{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:47:49Z","timestamp":1786373269511,"version":"build-2736575974"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"DOI":"10.13039\/501100006389","name":"Universit\u00e9 de Gen\u00e8ve","doi-asserted-by":"publisher","award":["2178281.02.0001"],"award-info":[{"award-number":["2178281.02.0001"]}],"id":[{"id":"10.13039\/501100006389","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008582","name":"McGill University","doi-asserted-by":"publisher","award":["Department of Medicine salary support"],"award-info":[{"award-number":["Department of Medicine salary support"]}],"id":[{"id":"10.13039\/100008582","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Prasugrel and ticagrelor have superior efficacy compared with clopidogrel in moderate CKD but have not been studied in kidney failure. The study objective is to determine the effectiveness and safety of prasugrel and ticagrelor in kidney failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>This retrospective cohort study used United States Renal Data System data from 2012 to 2015. We identified all patients on dialysis who received a drug-eluting stent and were alive at 90 days after stent implantation. Inverse probability\u2013weighted Cox proportional hazard models were used. Weights were estimated with propensity scores for multiple treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This cohort included 6648 patients on clopidogrel, 621 on prasugrel, and 449 on ticagrelor. A total of 3279 primary composite (cardiovascular death, myocardial infarction, or stroke) and 2120 clinically relevant bleeding events were observed. The incidence of the primary composite outcome of cardiovascular death, myocardial infarction, or stroke at 12 months was similar across the three treatment groups. The absolute event rate in the unweighted cohort was 144 events per 100 patient-years for clopidogrel, 126 for prasugrel, and 161 for ticagrelor. For prasugrel versus clopidogrel, the weighted hazard ratio was 0.96 (95% confidence interval, 0.82 to 1.11;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.58). For ticagrelor versus clopidogrel, the hazard ratio was 1.00 (95% confidence interval, 0.83 to 1.20;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.98). A numerically higher incidence of clinically relevant bleeding was seen with prasugrel or ticagrelor compared with clopidogrel (weighted hazard ratio, 1.15; 95% confidence interval, 0.95 to 1.38 and weighted hazard ratio, 1.13; 95% confidence interval, 0.91 to 1.40, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Prasugrel or ticagrelor does not seem to be associated with significant benefits compared with clopidogrel in patients with kidney failure treated with drug-eluting stents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Podcast<\/jats:title>\n                    <jats:p>This article contains a podcast at https:\/\/www.asn-online.org\/media\/podcast\/CJASN\/2021_04_02_CJN12120720.mp3<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.12120720","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T13:50:12Z","timestamp":1617371412000},"page":"757-764","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Prasugrel and Ticagrelor in Patients with Drug-Eluting Stents and Kidney Failure"],"prefix":"10.2215","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3368-247X","authenticated-orcid":false,"given":"Thomas A.","family":"Mavrakanas","sequence":"first","affiliation":[{"name":"Renal Division, Brigham & Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland"},{"name":"Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Kamal","sequence":"additional","affiliation":[{"name":"Renal Division, Brigham & Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7695-3583","authenticated-orcid":false,"given":"David M.","family":"Charytan","sequence":"additional","affiliation":[{"name":"Renal Division, Brigham & Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Nephrology, New York University Grossman School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,8]]},"reference":[{"key":"B1-20241015","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1161\/CIRCULATIONAHA.118.032078","article-title":"P2Y12-ADP receptor blockade in chronic kidney disease patients with acute coronary syndromes","volume":"138","author":"Bonello","year":"2018","journal-title":"Circulation"},{"key":"B2-20241015","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"B3-20241015","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"B4-20241015","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.kint.2016.09.049","article-title":"Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: A review","volume":"91","author":"Mathew","year":"2017","journal-title":"Kidney Int"},{"key":"B5-20241015","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1038\/sj.ki.5001934","article-title":"The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease","volume":"70","author":"Charytan","year":"2006","journal-title":"Kidney Int"},{"key":"B6-20241015","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ahj.2007.10.046","article-title":"The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial","volume":"155","author":"Best","year":"2008","journal-title":"Am Heart J"},{"key":"B7-20241015","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: Results from the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"122","author":"James","year":"2010","journal-title":"Circulation"},{"key":"B8-20241015","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/heartjnl-2017-312436","article-title":"Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction stratified by renal function","volume":"104","author":"Edfors","year":"2018","journal-title":"Heart"},{"key":"B9-20241015","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.jcin.2017.02.047","article-title":"Associations between chronic kidney disease and outcomes with use of prasugrel versus clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A report from the PROMETHEUS study","volume":"10","author":"Baber","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"B10-20241015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ehjcvp\/pvz048","article-title":"P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: An analysis from the RENAMI and BleeMACS projects","volume":"6","author":"De Filippo","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"B12-20241015","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1161\/CIRCULATIONAHA.112.001264","article-title":"Long-term survival and repeat coronary revascularization in dialysis patients after surgical and percutaneous coronary revascularization with drug-eluting and bare metal stents in the United States","volume":"127","author":"Shroff","year":"2013","journal-title":"Circulation"},{"key":"B13-20241015","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat Med"},{"key":"B14-20241015","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0895-4356(00)00321-8","article-title":"Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: A matched analysis using propensity scores","volume":"54","author":"Normand","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"B15-20241015","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.12120720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:44:12Z","timestamp":1786369452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.12120720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.12120720","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"2020-07-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}